Pateclizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pateclizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target lymphotoxin alpha
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6436H9910N1710O2004S44
Molar mass 144.7 kDa
 NYesY (what is this?)  (verify)

Pateclizumab is an immunomodulator. It binds to lymphotoxin alpha.[1][2]

This drug was developed by Genentech/Roche.

References[edit]

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2). 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.